Target type: biologicalprocess
Any process that decreases the rate, frequency, or extent of protein glutathionylation. Protein glutathionylation is the protein modification process in which a glutathione molecule is added to a protein amino acid through a disulfide linkage. [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]
Negative regulation of protein glutathionylation is a complex biological process that plays a critical role in maintaining cellular redox homeostasis and protecting cells from oxidative stress. Glutathionylation, the reversible attachment of glutathione (GSH) to cysteine residues of proteins, is a post-translational modification that can modulate protein activity, stability, and localization. While glutathionylation can be beneficial in protecting cells from oxidative damage, excessive glutathionylation can disrupt cellular function and contribute to disease pathogenesis. Therefore, cells have evolved sophisticated mechanisms to tightly regulate protein glutathionylation levels.
Negative regulation of protein glutathionylation involves multiple pathways and mechanisms, including:
- **Regulation of GSH levels:** GSH is the primary substrate for glutathionylation and its availability plays a critical role in determining the extent of glutathionylation. The cellular GSH pool is regulated by a complex interplay of enzymes involved in its synthesis, degradation, and transport. Factors such as nutrient availability, oxidative stress, and various signaling pathways can influence GSH levels and, consequently, protein glutathionylation.
- **Regulation of glutathione S-transferases (GSTs):** GSTs are a family of enzymes that catalyze the transfer of GSH to various substrates, including proteins. Different GST isoforms exhibit substrate specificity and are differentially regulated by various stimuli, allowing for precise control of protein glutathionylation in specific cellular contexts.
- **Regulation of glutaredoxins (Grxs):** Grxs are small redox proteins that play a critical role in deglutathionylation, the removal of GSH from proteins. Grxs utilize GSH as a reducing agent to catalyze the reduction of glutathionylated proteins, thereby reversing glutathionylation and restoring protein function.
- **Regulation of other deglutathionylating enzymes:** In addition to Grxs, other enzymes, such as thioredoxin reductase, thioredoxin, and sulfiredoxin, can also contribute to deglutathionylation, providing multiple levels of control over this process.
- **Regulation of protein interactions:** Protein-protein interactions can influence protein glutathionylation by modulating the accessibility of cysteine residues to GSH and by altering the activity of glutathionylating or deglutathionylating enzymes.
- **Regulation by other post-translational modifications:** Protein glutathionylation can be influenced by other post-translational modifications, such as phosphorylation, acetylation, and ubiquitination. These modifications can alter protein conformation and the accessibility of cysteine residues, thereby influencing glutathionylation.
Overall, negative regulation of protein glutathionylation is a dynamic and intricate process that involves a complex interplay of various factors. Precise control of this process is crucial for maintaining cellular redox homeostasis, protecting cells from oxidative stress, and ensuring proper cellular function. Dysregulation of protein glutathionylation has been implicated in the pathogenesis of various diseases, highlighting the importance of understanding the molecular mechanisms underlying this process.'
"
Protein | Definition | Taxonomy |
---|---|---|
Glucose-6-phosphate 1-dehydrogenase | A glucose-6-phosphate 1-dehydrogenase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P11413] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
furosemide | furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure. Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. | chlorobenzoic acid; furans; sulfonamide | environmental contaminant; loop diuretic; xenobiotic |
ketotifen | ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect. Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. | cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound | anti-asthmatic drug; H1-receptor antagonist |
thymidine | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite | |
methylprednisolone acetate | methylprednisolone acetate : An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid. Methylprednisolone Acetate: Methylprednisolone derivative that is used as an anti-inflammatory agent for the treatment of ALLERGY and ALLERGIC RHINITIS; ASTHMA; and BURSITIS; and for the treatment of ADRENAL INSUFFICIENCY. | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; glucocorticoid; steroid ester; tertiary alpha-hydroxy ketone | anti-inflammatory drug |
androsterone | 17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid | androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone | |
dehydroepiandrosterone | dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands. Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. | 17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid | androgen; human metabolite; mouse metabolite |
pregnenolone | 20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid | human metabolite; mouse metabolite | |
16-bromoepiandrosterone | 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one: a synthetic adrenal hormone that reduced the incidence of tuberculosis and other opportunistic infections in AIDS patients | ||
brexanolone | brexanolone : A 3-hydroxy-5alpha-pregnan-20-one in which the hydroxy group at position 3 has alpha-configuration. It is a metabolite of the sex hormone progesterone and used for the treatment of postpartum depression in women. brexanolone: a mixture of allopregnanolone and sulfobutylether‐beta‐cyclodextrin for treatment of postpartum depression | 3-hydroxy-5alpha-pregnan-20-one | antidepressant; GABA modulator; human metabolite; intravenous anaesthetic; sedative |
tetrahydrodeoxycorticosterone | tetrahydrodeoxycorticosterone: RN given refers to (3alpha,5beta)-isomer | 21-hydroxy steroid | |
16-hydroxydehydroepiandrosterone | 16-hydroxydehydroepiandrosterone: RN refers to (3beta,16alpha)-isomer | 16alpha-hydroxy steroid; 17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid; secondary alpha-hydroxy ketone | human metabolite; mouse metabolite |
methotrexate | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent | |
21-hydroxypregnenolone | 21-hydroxypregnenolone : A hydroxypregnenolone that is pregnenolone which has been substituted by a hydroxy group at position 21. 21-hydroxypregnenolone: RN given refers to (3beta)-isomer; | 21-hydroxy steroid; hydroxypregnenolone; primary alpha-hydroxy ketone | mouse metabolite |
epiandrosterone | epiandrosterone : A 3beta-hydroxy steroid that is (5alpha)-androstane substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. | 17-oxo steroid; 3beta-hydroxy steroid; androstanoid | androgen; human metabolite |
paricalcitol | hydroxy seco-steroid; seco-cholestane | antiparathyroid drug | |
polydatin | trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue. | beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid | anti-arrhythmia drug; antioxidant; geroprotector; hepatoprotective agent; metabolite; nephroprotective agent; potassium channel modulator |
wedelolactone | wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3. wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source | aromatic ether; coumestans; delta-lactone; polyphenol | antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite |
quercetin | |||
indigo carmine | 3,5-di-O-(E)-caffeoylquinic acid: from roots of Lychnophora ericoides; structure in first source 3,5-di-O-caffeoyl quinic acid : A carboxylic ester that is the diester obtained by the condensation of the hydroxy groups at positions 3 and 5 of (-)-quinic acid with the carboxy group of trans-caffeic acid. Isolated from Brazilian propolis and Suaeda glauca, it exhibits hepatoprotective and cytotoxic activities. | ||
thiocolchicoside | thiocolchicoside: used in combination with glafenine and meprobamate to tranquilize patients undergoing hysterosalpingography; structure | glycoside | |
ml276 | |||
mobic | meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis. Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS. | 1,3-thiazoles; benzothiazine; monocarboxylic acid amide | analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug |
olanzapine | olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4. Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy. | benzodiazepine; N-arylpiperazine; N-methylpiperazine | antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor |